Pharmaceutical - Asia-Pacific, Diabetes


Current filters:


Popular Filters

1 to 25 of 44 results

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children


Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…


Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan


Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Australian patients benefit from PBS changes; cancer research


New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing…


India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector


The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat


Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients


Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds


Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Indication changes for Glufast approved in Japan


Japanese drugmakers Kissei Pharmaceutical (TYO: 4547) and Takeda Pharmaceutical (TYO: 4502) have received…

Asia-PacificDiabetesGlufastKissei PharmaceuticalPharmaceuticalRegulationTakeda Pharmaceuticals

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

Sirona Biochem signs LoI with leading Chinese diabetes company


Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Growth drivers for China's type 2 diabetes market


The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Takeda gains Chinese approval for diabetes drug


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

Zydus' diabetes drug Lipaglyn becomes India's first NCE to reach the market


Indian drugmaker Zydus Cadila today (June 5) made a breakthrough in its research efforts with Lipaglyn…

Asia-PacificDiabetesLipaglynPharmaceuticalRegulationZydus Cadila

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Merck KGaA links with Bristol-Myers for Glucophage promotion in China


German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

Astellas files for Japanese approval of ipragliflozin for types 2 diabetes


Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for…

Asia-PacificAstellas PharmaDiabetesipragliflozinPharmaceuticalRegulation

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord


Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin


Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review


Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Russia's Renova invests in Novelos; Novo Nordisk opens Vietnam office


USA-based Novelos Therapeutics (OTCQX: NVLT), which is developing novel drugs for the treatment and diagnosis…

Asia-PacificDiabetesFinancialMarkets & MarketingNovelos TherapeuticsNovo NordiskOncologyPharmaceutical

1 to 25 of 44 results

Back to top